IBRX

ImmunityBio, Inc.

Healthcare · Biotechnology

$162.74 sample

-2.39 (-1.45%) 1D

Market cap

$907.7B

Price as of

2026-10-15

Latest filing

8-K · 2026-10-12

Alerts

8

Price$162.74 +1.07% 3M daily closessample

166.81157.61

2026-07-202026-08-112026-09-022026-09-232026-10-15

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 12SEC10-Q filed
Oct 01INSInsider sell: Director
Sep 25INSInsider sell: Chief Executive Officer
Sep 21SEC8-K filed: material event
Sep 15SECDEF 14A filed
Sep 07INSInsider buy: General Counsel
Aug 28INSInsider buy: EVP, Operations
Aug 24INSInsider sell: Chief Executive Officer

Sign up to see the real IBRX record →

Company facts

SEC EDGAR registration

Name: ImmunityBio, Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: -39sample, -100 to +100
Reporting currency: USD

Who is positioning in IBRX

sample

Insiders: 15 insider transactions over 90 days, net selling, $477.1M
Congress: 4 members traded over 90 days
Institutions · 13F: 34 funds hold $5.0B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$29.5B +18.8% y/y

Q4 2024Q3 2026

Inventory$17.9B +12.3% y/y

Q4 2024Q3 2026

Accounts receivable$13.7B +14.7% y/y

Q4 2024Q3 2026

Total debt$36.0B +11.1% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $586.6B -8.0% 3M
Sample peer B: $784.9B +14.3% 3M
Sample peer C: $584.9B -9.4% 3M
Sample peer D: $226.3B -2.6% 3M
Sample peer E: $589.1B +14.5% 3M